Jaguar Health

Jaguar Health announces that subsidiary Napo Pharmaceuticals will provide crofelemer powder to manufacture an oral solution for the treatment of microvillus inclusion disease (MVID) and plans to file an application with the FDA in mid-2027. The company may seek Breakthrough Therapy Designation if appropriate. Clinical data showed a reduction in the need for parenteral nutrition in pediatric patients with no significant clinical abnormalities after more than one year of treatment. » More on de.investing.com

Jaguar Health has introduced Neonorm Dog, an over-the-counter plant-based product to support stool consistency and fluid balance in dogs’ gastrointestinal tract. The formulation contains a standardized extract from the Croton lechleri tree and complements the existing Neonorm line for foals and calves. Neonorm Dog will be sold through selected online and specialty channels such as Amazon and Chewy and is intended as an alternative to home remedies, not a replacement for veterinary care. » More on de.investing.com

Jaguar Health reported data on liquid oral crofelemer in pediatric patients with intestinal failure showing a reduced need for parenteral support. In one patient with MVID, the weekly weight‑normalized requirement decreased by up to 48% after more than 12 months; two children with short bowel syndrome showed reductions of up to 40%. The treatment was well tolerated. The company intends to seek Breakthrough Therapy designation for crofelemer in MVID and plans an FDA approval submission in mid‑2027. » More on de.investing.com